Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Immuron | IMM-529 | Clostridium Difficile Infection | Phase I/II trials initiated enrolling 60 subjects |
| SillaJen | pexastimogene devacirepvec (Pexa-Vec) | metastatic colon cancer | Phase I/II trials initiated |
| Mapi Pharma | GA Depot | primary progressive multiple sclerosis | Phase II trials initiated enrolling 12-24 subjects |
| Merus | MCLA-128 | metastatic breast cancer | Phase II trials initiated enrolling 120 subjects in the U.S. and Europe |
| Novan | SB206 | molluscum contagiosum | Phase II trials initiated enrolling 192 children and adolescents |
| Aldeyra Therapeutics | topical ocular reproxalap | dry eye disease | Phase IIb trials initiated enrolling 300 subjects |
| Dermira | lebrikizumab | moderate to severe atopic dermatitis | Phase IIb trials initiated enrolling 350 subjects in the U.S. |
| BeiGene | tislelizumab | advanced unresectable or metastatic esophageal squamous cell carcinoma | Phase III trials initiated enrolling 350 subjects globally |
| Cara Therapeutics | Korsuva (CR845/difelikefalin) | hemodialysis patients suffering from moderate to severe chronic kidney disease-associated pruritus | Phase III trials initiated enrolling 350 subjects in the U.S. |
| Diffusion Pharmaceuticals | trans sodium crocetinate | newly-diagnosed inoperable glioblastoma multiforme | Phase III trials initiated enrolling 264 subjects |
| Aquestive Therapeutics | Riluzole Oral Soluble Film | amyotrophic lateral sclerosis | Orphan Drug designation granted by the FDA |
| Dauntless Pharmaceuticals | DP1038 | acromegaly | Orphan Drug designation granted by the FDA |
| Ensysce Biosciences | PF614 | moderate to severe chronic pain | Fast Track designation granted by the FDA |
| Faron Pharmaceuticals | Traumakine | acute respiratory distress syndrome | Fast Track designation granted by the FDA |
| Protalix Biotherapeutics | PRX-102 | Fabry disease | Fast Track designation granted by the FDA |
| Synthon | [vic-]trastuzumab duocarmazine (SYD985) | HER2-positive metastatic breast cancer | Fast Track designation granted by the FDA |
| Takeda Pharmaceutical | TAK-426 | Zika virus vaccine | Fast Track designation granted by the FDA |
| LimFlow | LimFlow Percutaneous Deep Vein Arterialization System | end-stage critical limb ischemia | Breakthrough Device designation granted by the FDA |
| Roche | balovaptan | autism spectrum disorder | Breakthrough Therapy Designation granted by the FDA |
| AngioDynamics | NanoKnife System | stage III pancreatic cancer | Expedited Access Pathway designation granted by the FDA |
| Abeona Therapeutics | EB-101 | recessive dystrophic epidermolysis bullosa | Regenerative Medicine Advanced Therapy designation granted by the FDA |
| CutisPharma | CutisPharma Firvanq (vancomycin hydrochloride) | Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus | FDA approved |
| Synergy Pharmaceuticals | Trulance (plecanatide) | irritable bowel syndrome with constipation | FDA approved |
Upcoming Events
-
25May
-
28Jun
-
16Oct
